Leerink Partners analyst Joseph Schwartz lowered his price target on Zafgen (NASDAQ: ZFGN) to $46.00 (from $56.00) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

RBC Capital Sees Attractive Risk/Reward in Zafgen (ZFGN)October 19, 2015 10:13 AM UPDATE: FBR Downgrades Zafgen (ZFGN) to Sector PerformOctober 16, 2015 2:56 PM Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death October 16, 2015 1:28 PM Form 8-K ZAFGEN, INC. For: Oct 16October 16, 2015 7:26 AM Zafgen's (ZFGN) Beloranib Placed on Partial Clinical Hold by FDAOctober 16, 2015 6:31 AM